Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. develops the investigational Aethlon Hemopurifier, an extracorporeal therapeutic device for oncology and other indications. Company news centers on clinical-stage development in solid tumors and infectious-disease applications, including safety, feasibility and dose-finding work for Hemopurifier treatments used alongside anti-PD-1 therapies such as pembrolizumab or nivolumab.
Recurring updates also address preclinical research on the device's GNA affinity resin, extracellular vesicle removal and inflammatory microRNAs, along with quarterly financial results, corporate updates and investor presentations. The company's disclosures describe a platform designed to selectively remove circulating pathogenic targets from biologic fluids.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.